Article Type
Changed
Thu, 12/15/2022 - 15:07
Display Headline
New Developments in Chronic Lymphocytic Leukemia Treatment
Dr. Sanjai Sharma discusses what new developments in research focused on signaling pathways in CLL means for patients with the disease.

Recently, Federal Practitioner talked with Sanjai Sharma, MD, about how signaling pathways in chronic lymphocytic leukemia (CLL) is critical to the development of therapeutic agents to treat this disease. Ibrutinib and idelalisib are therapeutic agents that block signaling pathways and, therefore, inhibit the growth of CLL cells.

For more information about CLL, read "Signaling Pathways and Novel Inhibitors in Chronic Lymphocytic Leukemia," in our August 2014 issue.

 

 

 

Dr. Sharma is a physician at the West Los Angeles VA Medical Center and associate professor in the Department of Medicine, Hematology/Oncology at UCLA, both in California.

Publications
Topics
Legacy Keywords
Leukemia, chronic lymphocytic leukemia, cancer, oncology, hematology, veterans affairs, signaling pathways, CLL, ibrutinib, idelalisib
Sections
Related Articles
Dr. Sanjai Sharma discusses what new developments in research focused on signaling pathways in CLL means for patients with the disease.
Dr. Sanjai Sharma discusses what new developments in research focused on signaling pathways in CLL means for patients with the disease.

Recently, Federal Practitioner talked with Sanjai Sharma, MD, about how signaling pathways in chronic lymphocytic leukemia (CLL) is critical to the development of therapeutic agents to treat this disease. Ibrutinib and idelalisib are therapeutic agents that block signaling pathways and, therefore, inhibit the growth of CLL cells.

For more information about CLL, read "Signaling Pathways and Novel Inhibitors in Chronic Lymphocytic Leukemia," in our August 2014 issue.

 

 

 

Dr. Sharma is a physician at the West Los Angeles VA Medical Center and associate professor in the Department of Medicine, Hematology/Oncology at UCLA, both in California.

Recently, Federal Practitioner talked with Sanjai Sharma, MD, about how signaling pathways in chronic lymphocytic leukemia (CLL) is critical to the development of therapeutic agents to treat this disease. Ibrutinib and idelalisib are therapeutic agents that block signaling pathways and, therefore, inhibit the growth of CLL cells.

For more information about CLL, read "Signaling Pathways and Novel Inhibitors in Chronic Lymphocytic Leukemia," in our August 2014 issue.

 

 

 

Dr. Sharma is a physician at the West Los Angeles VA Medical Center and associate professor in the Department of Medicine, Hematology/Oncology at UCLA, both in California.

Publications
Publications
Topics
Article Type
Display Headline
New Developments in Chronic Lymphocytic Leukemia Treatment
Display Headline
New Developments in Chronic Lymphocytic Leukemia Treatment
Legacy Keywords
Leukemia, chronic lymphocytic leukemia, cancer, oncology, hematology, veterans affairs, signaling pathways, CLL, ibrutinib, idelalisib
Legacy Keywords
Leukemia, chronic lymphocytic leukemia, cancer, oncology, hematology, veterans affairs, signaling pathways, CLL, ibrutinib, idelalisib
Sections
Disallow All Ads